Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | HCAR2 | Q8TDS4 | 3/20 | 0.48 |
| ▸ | MAOA | P21397 | 2/20 | 0.48 |
| ▸ | MAOB | P27338 | 2/20 | 0.48 |
| ▸ | DAO | P14920 | 1/20 | 0.45 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.45 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.45 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.42 |
| ▸ | TNKS | O95271 | 1/20 | 0.42 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.42 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.42 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL77017 | 1.00 | MAPK1 (0.56) | MAPK1KMT2AHCAR2MAOAMAOB | |
| SCHEMBL8920408 | 0.85 | MAPK1 (0.66) | MAPK1KMT2AHCAR2TBXAS1HDAC3 | |
| SCHEMBL8920416 | 0.85 | MAPK1 (0.66) | MAPK1KMT2AHCAR2TBXAS1HDAC3 | |
| SCHEMBL4607447 | 0.85 | MAOA (0.46) | MAPK1KMT2AHCAR2MAOAMAOB | |
| SCHEMBL4607453 | 0.85 | MAOA (0.46) | MAPK1KMT2AHCAR2MAOAMAOB | |
| SCHEMBL9520373 | 0.84 | MAOA (0.51) | MAPK1KMT2AMAOAMAOBDAO | |
| SCHEMBL9520363 | 0.84 | MAOA (0.51) | MAPK1KMT2AMAOAMAOBDAO | |
| SCHEMBL28718615 | 0.80 | MAPK1 (0.56) | MAPK1KMT2AHCAR2TBXAS1HDAC3 | |
| SCHEMBL28718616 | 0.80 | MAPK1 (0.56) | MAPK1KMT2AHCAR2TBXAS1HDAC3 | |
| SCHEMBL3516804 | 0.78 | MAOA (0.47) | MAPK1KMT2AMAOAMAOBDAO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118647270-A | Novel derivatives of non-coding amino acids and their use as herbicides | 福提费斯特有限公司 | 2024-09-13 | — | — | CN | claimed |
| WO-2023131951-A1 | NOVEL DERIVATIVES OF NON-CODED AMINO ACIDS AND THEIR USE AS HERBICIDES | FORTEPHEST LTD. (IL) | 2023-07-13 | — | — | WO | claimed |
| CN-118647270-A | Novel derivatives of non-coding amino acids and their use as herbicides | 福提费斯特有限公司 | 2024-09-13 | — | — | CN | disclosed |
| US-11896593-B2 | Sulfamate derivative compounds for use in treating or alleviating a psychiatric disorder | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2024-02-13 | — | — | US | disclosed |
| EP-4308230-A1 | HETEROARYL INHIBITORS OF PLASMA KALLIKREIN | Takeda Pharmaceutical Company Limited (JP) | 2024-01-24 | — | — | EP | disclosed |
| CN-117355521-A | Heteroaryl inhibitors of plasma kallikrein | 武田药品工业株式会社 | 2024-01-05 | — | — | CN | disclosed |
| EP-4211125-A1 | SULFAMATE DERIVATIVE COMPOUNDS FOR USE IN TREATING OR ALLEVIATING A PSYCHIATRIC DISORDER | Bio-Pharm Solutions Co., Ltd. (KR) | 2023-07-19 | — | — | EP | disclosed |
| WO-2023131951-A1 | NOVEL DERIVATIVES OF NON-CODED AMINO ACIDS AND THEIR USE AS HERBICIDES | FORTEPHEST LTD. (IL) | 2023-07-13 | — | — | WO | disclosed |
| WO-2022197758-A1 | HETEROARYL INHIBITORS OF PLASMA KALLIKREIN | SHIRE HUMAN GENETIC THERAPIES, INC. (US) | 2022-09-22 | — | — | WO | disclosed |
| US-20220218702-A1 | SULFAMATE DERIVATIVE COMPOUNDS FOR USE IN TREATING OR ALLEVIATING A PSYCHIATRIC DISORDER | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2022-07-14 | — | — | US | disclosed |
| EP-3443959-A1 | SULFAMATE DERIVATIVE COMPOUNDS FOR USE IN TREATING OR ALLEVIATING PAIN | Bio-Pharm Solutions Co., Ltd. (KR) | 2019-02-20 | — | — | EP | disclosed |
| EP-1086099-A1 | SULFONIC ACID OR SULFONYLAMINO N-(HETEROARALKYL)-AZAHETEROCYCLYLAMIDE COMPOUNDS | Aventis Pharmaceuticals Products Inc. (US) | 2001-03-28 | — | — | EP | disclosed |
| WO-2001007436-A2 | SUBSTITUTED OXOAZAHETEROCYCLYL COMPOUNDS | AVENTIS PHARMACEUTICALS INC. (US) | 2001-02-01 | — | — | WO | disclosed |
| EP-1051176-A1 | SUBSTITUTED OXOAZAHETEROCYCLYL FACTOR Xa INHIBITORS | Aventis Pharmaceuticals Products Inc. (US) | 2000-11-15 | — | — | EP | disclosed |
| WO-2000032590-A1 | SUBSTITUTED OXOAZAHETEROCYCLYL FACTOR Xa INHIBITORS | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 2000-06-08 | — | — | WO | disclosed |
| WO-1999062904-A1 | SULFONIC ACID OR SULFONYLAMINO N-(HETEROARALKYL)-AZAHETEROCYCLYLAMIDE COMPOUNDS | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 1999-12-09 | — | — | WO | disclosed |
| WO-1999037304-A1 | SUBSTITUTED OXOAZAHETEROCYCLYL FACTOR Xa INHIBITORS | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 1999-07-29 | — | — | WO | disclosed |
| US-5145868-A | 7-((Hydroxy(3-hydroxy-4-acylphenyl)alkylene)thio-),4-oxo-4H -chromene; antiallergens; leukotrienes antagonist | CIBA-GEIGY CORPORATION (US) | 1992-09-08 | — | — | US | disclosed |
| EP-0419410-A2 | Alkanophenones | CIBA-GEIGY AG (CH) | 1991-03-27 | — | — | EP | disclosed |
| US-4093622-A | Pyridine esters of cyclopropane-carboxylic acid | ZOECON CORPORATION (US) | 1978-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220218702-A1 | SULFAMATE DERIVATIVE COMPOUNDS FOR USE IN TREATING OR ALLEVIATING A PSYCHIATRIC DISORDER | SLC6A4, SLC6A3, SLC6A2 | MAPK1 1343/4885KMT2A 388/4885HCAR2 693/4885 |
| US-11896593-B2 | Sulfamate derivative compounds for use in treating or alleviating a psychiatric disorder | SLC6A4, SLC6A3, SLC6A2 | MAPK1 1343/4885KMT2A 388/4885HCAR2 693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.